First-line therapy in adult Crohn's disease: Who should receive anti-TNF agents?

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 6, 2013, Pages 345-351

  Peyrin Biroulet, Laurent ^a   Fiorino, Gionata ^b   Buisson, Anthony ^a   Danese, Silvio ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; CANCER RISK; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INTESTINE SURGERY; MEDICAL DECISION MAKING; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SURGICAL RISK; T CELL LYMPHOMA; TREATMENT DURATION; TUBERCULOSIS; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; CROHN DISEASE; HUMANS; METHOTREXATE; PATIENT SELECTION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878951773     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.31     Document Type: Review

References (60)

1. Peyrin-Biroulet, L. et al. Disability in inflammatory bowel diseases: Developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm. Bowel Dis. 16, 15-22 (2010
2. Peyrin-Biroulet, L. et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 61, 241-247 (2012
3. Pariente, B. et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm. Bowel Dis. 17, 1415-1422 (2011
4. Peyrin-Biroulet, L., Loftus, E. V. Jr, Colombel, J. F. & Sandborn, W. J. The natural history of adult Crohn's disease in population-based cohorts. Am. J. Gastroenterol. 105, 289-297 (2010
5. Peyrin-Biroulet, L., Loftus, E. V. Jr, Colombel, J. F. & Sandborn, W. J. Long-Term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm. Bowel Dis. 17, 471-478 (2011
6. Thia, K. T., Sandborn, W. J., Harmsen, W. S., Zinsmeister, A. R. & Loftus, E. V. Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 139, 1147-1155 (2010
7. Buisson, A., Chevaux, J. B., Bommelaer, G. & Peyrin-Biroulet, L. Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence. Dig. Liver Dis. 44, 453-460 (2012
8. Buisson, A., Chevaux, J. B., Allen, P. B., Bommelaer, G. & Peyrin-Biroulet, L. Review article: The natural history of postoperative Crohn's disease recurrence. Aliment. Pharmacol. Ther. 35, 625-633 (2012
9. Casellas, F., López-Vivancos, J., Vergara, M. & Malagelada, J. Impact of inflammatory bowel disease on health-related quality of life. Dig. Dis. 17, 208-218 (1999
10. Etchevers, M. J., Aceituno, M. & Sans, M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J. Gastroenterol. 14, 5512-5518 (2008
11. Pineton de Chambrun, G., Peyrin-Biroulet, L., Lémann, M. & Colombel, J. F. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. 7, 15-29 (2010
12. Dignass, A. et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J. Crohns Colitis 4, 28-62 (2010
13. Marck Sharp & Dohme Limited. Remicade 100 mg powder for concentrate for solution for infusion. electronic Medicines Compendium [online], http://www.medicines.org.uk/emc/medicine/3236 (2011
14. European Medicines Agency. Humira. European Medicines Agency [online], http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000481/human-med-000822.jsp&mid=WC0b01ac058001d124 (2013
15. European Medicines Agency. Cimzia. European Medicines Agency [online], http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000740/human-med-000700.jsp&mid=WC0b01ac058001d124 (2013
16. US Department of Health & Human Services. Infliximab product information-licensing action. FDA [online], http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm093333.htm (2009
17. US Department of Health & Human Services. Adalimumab product approval information-licensing action 12/31/02. FDA [online], http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm080610.htm (2009
18. US Department of Health and Human Services. Drugs@FDA: FDA Approved Drug Products. FDA [online], http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?CFID=3669758&CFTOKEN=520738f2674fb681 312BA32D BB28 EF03 E45C8B0B657001AD#labelinfo (2013
19. Bouguen, G. & Peyrin-Biroulet, L. Surgery for adult Crohn's disease: What is the actual risk? Gut 60, 1178-1181 (2011
20. Present, D. H. et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340, 1398-1405 (1999
21. Sands, B. E. et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350, 876-885 (2004
22. Hanauer, S. B. et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359, 1541-1549 (2002
23. Sandborn, W. J. et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann. Intern. Med. 146, 829-838 (2007
24. Colombel, J. F. et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 58, 940-948 (2009
25. Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 132, 52-65 (2007
26. Van Assche, G. et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J. Crohns Colitis 4, 63-101 (2010
27. Lichtenstein, G. R., Hanauer, S. B. & Sandborn, W. J. Management of Crohn's disease in adults. Am. J. Gastroenterol. 104, 465-483 (2009
28. Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010
29. Beaugerie, L. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet 374, 1617-1625 (2009
30. Chevaux, J. B., Peyrin-Biroulet, L. & Sparrow, M. P. Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm. Bowel Dis. 17, 1428-1435 (2011
31. Markowitz, J., Grancher, K., Kohn, N., Lesser, M. & Daum, F. A multicenter trial of 6 mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119, 895-902 (2000
32. Sans, M. et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's Disease patients. Gastroenterology 140 (Suppl. 1), S109 (2011
33. Cosnes, J. et al. Accelerated step-care therapy with early azathioprine (AZA) vs. conventional step-care therapy in Crohn's disease: A randomized study [abstract 943c]. Gastroenterology 142 (Suppl. 1), S161 (2012
34. Peyrin-Biroulet, L. et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 141, 1621-1628 (2011
35. Danese, S. & Peyrin-Biroulet, L. IBD: Mucosal healing-EXTENDing our knowledge in Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 9, 309-311 (2012
36. Rutgeerts, P. et al. Adalimumab induces and maintains mucosal healing in patients with crohn's disease: Data from the EXTEND trial. Gastroenterology 142, 1102-1111 (2012
37. Peyrin-Biroulet, L. et al. Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease. J. Crohns Colitis 5, 477-483 (2011
38. Peyrin-Biroulet, L. et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 60, 930-936 (2011
39. Peyrin-Biroulet, L., Loftus, E. V. Jr, Colombel, J. F. & Sandborn, W. J. Early Crohn disease: A proposed definition for use in disease-modification trials. Gut 59, 141-147 (2010
40. Sandborn, W. J. et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 228-238 (2007
41. Schreiber, S. et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: An analysis of PRECiSE 2 randomized maintenance trial data. Am. J. Gastroenterol. 105, 1574-1582 (2010
42. D'Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial. Lancet 371, 660-667 (2008
43. Peyrin-Biroulet, L., Billioud, V. & D'Haens, G. Development of the Paris definition of early Crohn's disease for disease-modification trials: Results of an international expert opinion process. Am. J. Gastroenterol. 107, 1770-1776 (2012
44. Best, W. R., Becktel, J. M., Singleton, J. W. & Kern, F. Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70, 439-444 (1976
45. Vavricka, S. R. et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am. J. Gastroenterol. 106, 110-119 (2011
46. Zallot, C. & Peyrin-Biroulet, L. Clinical risk factors for complicated: How reliable are they? Dig. Dis. 30 (Suppl. 3), 67-72 (2012
47. Peyrin-Biroulet, L. et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-Analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6, 644-653 (2008
48. Fidder, H. et al. Long-Term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study. Gut 58, 501-508 (2009
49. Colombel, J. F. et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 15, 1308-1319 (2009
50. Seminerio, J. L., Loftus, E. V. Jr, Colombel, J. F., Thapa, P. & Sandborn, W. J. Infliximab for Crohn's Disease: The first 500 patients followed up through 2009. Dig. Dis. Sci. http://dx.doi.org/10.1007/s10620 012 2405 z (2012
51. Lichtenstein, G. R. et al. A pooled analysis of infections, malignancy, and mortality in infliximab-And immunomodulator-Treated adult patients with inflammatory bowel disease. Am. J. Gastroenterol. 107, 1051-1063 (2012
52. Siegel, C. A., Marden, S. M., Persing, S. M., Larson, R. J. & Sands, B. E. Risk of lymphoma associated with combination anti-Tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-Analysis. Clin. Gastroenterol. Hepatol. 7, 874-881 (2009
53. Deepak, P. et al. T cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-A (TNF a) inhibitors: Results of the REFURBISH study. Am. J. Gastroenterol. 108, 99-105 (2013
54. Kotlyar, D. S. et al. A systematic review of factors that contribute to hepatosplenic T cell lymphoma in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 9, 36-41 (2011
55. Beaugerie, L. Immunosuppression-related lymphomas and cancers in IBD: How can they be prevented? Dig. Dis. 30, 415-419 (2012
56. Cottone, M. et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-Tumor necrosis factor therapy for inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 9, 30-35 (2011
57. Sprakes, M. B. et al. Costs of care for Crohn's disease following the introduction of infliximab: A single-centre UK experience. Aliment. Pharmacol. Ther. 32, 1357-1363 (2010
58. Dretzke, J. et al. A systematic review and economic evaluation of the use of tumour necrosis factor-A (TNF a) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol. Assess. 15, 1-244 (2011
59. Blackhouse, G. et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti TNF a drugs for refractory Crohn's disease. J. Crohns Colitis 6, 77-85 (2012
60. Ordás, I., Feagan, B. G. & Sandborn, W. J. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: Time for a change. Gut 60, 1754-1763 (2011